CBHAAlternative Names: M-carboxycinnamic acid bishydroxamide
Latest Information Update: 29 Apr 2002
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neuroblastoma
Most Recent Events
- 02 Dec 1999 New profile
- 02 Dec 1999 Preclinical development for Neuroblastoma in USA (Unknown route)